INTRODUCTION
Atherosclerotic plaque rupture induced coronary thrombus and the interruption of coronary blood flow are the main mechanisms initiating acute coronary syndromes (ACS) (ref. 1 ). Coronary thrombus burden is one of the risk factors for long and short term adverse cardiovascular events in ACS (ref. 2 ). Thrombus burden has impact on the success of the percutaneous coronary intervention (PCI) in ACS (ref. 3 ). Even several invasive and pharmacological treatment modalities have been introduced, intracoronary thrombus management is still insufficient. Therefore, determining the factors in prediction of intracoronary thrombus burden has great importance in forecasting adverse cardiovascular events as well as determining the most appropriate treatment strategy to prevent any failure in PCI.
Epicardial adipose tissue (EAT) is a true visceral fat depot localized beneath the visceral pericardium. It has become evident that EAT is a metabolically active organ producing proinflammatory and proatherogenic cytokines 4 . Increased EAT was associated with coronary no-reflow, coronary artery disease, hypertension (HT), insulin resistance and metabolic syndrome 5 . Given the potential paracrine effects of EAT, its distance from the epicardial coronaries and myocardial interstitium may be important factors in the development of myocardial microvascular dysfunction and thrombus formation 4 .
Previously, it was reported that inflammation was independently related to both no-reflow phenomenon and the coronary thrombus formation in ACS (ref. 6 ). The aim of this study was to evaluate the relationship between EAT thickness and thrombus burden in patients with STEMI who undergo primary PCI (pPCI).
METHODS

Study Population
The study recruited 156 patients prospectively. Patients who were referred to Kosuyolu Research and Education hospital with STEMI between 2016 and 2017 were enrolled into the study. The inclusion criteria were (1) presentation within the first 12 h after the onset of chest pain (18 hours for cardiogenic shock) and no history of thrombolytic therapy and (2) presence of an STsegment elevation at least 1 mm (2 mm for V1-V3) in 2 or more contiguous leads in electrocardiography (ECG). The patients who underwent thrombolytic therapy due to STEMI within 24 h, cardiogenic shock on admission, had active infection, pre-diagnosed systemic inflammatory disease history, liver disease, renal failure were excluded. The study protocol was approved by the institutional review board in our center and informed consent was obtained from all of the patients.
The following data were recorded during the hospitalization; detailed medical history, complete physical examination, cardiovascular risk factors including age, sex, family history of coronary artery disease (CAD), current smoking status, HT, dyslipidemia, and diabetes mellitus (DM). Furthermore, the body mass index (BMI; 
Echocardiographic analysis
Transthoracic echocardiography was performed in the left lateral decubitus position using a Vivid S5 system (GE Vingmed Ultrasound AS, Norten, Norway) with a 2.5 MHz phased-array transducer. Transthoracic echocardiographic examinations were done by an experienced echocardiographer blinded to the study protocol according to the recommendations of the American Society of Echocardiography 7 . Left ventricular ejection fraction (LVEF) was determined using modified Simpson's method 8 . EAT, identified as an echo-free space between the myocardium and visceral pericardium ,was measured perpendicularly, on the free wall of the right ventricle from both parasternal long-axis and short-axis views at end diastole in three cardiac cycles 9 . The maximum values at each site were quantified and the average value was used for the statistical analysis.
Angiographic analysis
Following the diagnosis of STEMI, the patients underwent emergency coronary angiography. All patients were administered as loading dose of 300 mg of acetylsalicylicacid and clopidogrel (600 mg) before the coronary intervention. Intravenous bolus of heparin (100U/kg) was given to all cases and platelet GP IIb/IIIa inhibitors (tirofiban) were given in the catheterization laboratory at the discretion of the operator during coronary angiography. pPCI was performed using the standard femoral approach with a 7-Fr guiding catheter. Coronary angiograms were recorded in right and left oblique planes using cranial and caudal angulations, at a rate of 30 frames/s. During coronary angiography, iopromide (Ultravist 370, Schering AG, Berlin, Germany) was used as the contrast agent in all patients. After these standard procedures, angiographic thrombus burden was scored in five grades: 0 (no thrombus), 1 (possible thrombus), 2 (definite thrombus <0.5 x reference vessel diameter), 3 (definite thrombus 0.5-2 x reference vessel diameters), 4 (definite thrombus > 2 x reference vessel diameters), and 5 (complete vessel occlusion) as previously described 10 . The patients were grouped into 2 categories of thrombus grade as low thrombus burden (grades 0-3) and high thrombus burden (grades 4 and 5).
Statistical analysis
Statistical analysis were performed using the statistical package SPSS for Windows (Version 20.0; SPSS, Chicago, IL). Distribution of data was assessed by using one-sample Kolmogorov-Smirnov test. Values displaying normal distribution were expressed as mean ± SD, whereas values displaying non-normal distribution were expressed as median with interquartile range. Categorical variables were expressed as percentages. In case of no significant deviation from normality, significance of differences between 2 groups was tested with Student's ttest, otherwise Mann-Whitney U-test was used. Logistic regression analysis (univariate and multivariate) was used to assess the independent predictors of thrombus burden. White blood cell(WBC), EAT and waist circumference were used as independent covariates in the model. A receiver-operating characteristic (ROC) curve analysis was performed to determine the cutoff value of EAT to predict the presence of high thrombus burden (grade 4 and 5). A significance level was set at P<0.05.
RESUlTS
A total of 156 patients were included in this study (51 in the low thrombus burden group and 105 in the high thrombus burden group). Baseline clinical, demographic features and laboratory findings of the two groups are shown in Table 1 . There were no differences in the two groups for LVEF, smoking, family history of CAD, DM, HT, and hypercholesterolemia and for total cholesterol, triglyceride, GFR, LDL-C and HDL-C. Also, no significant differences were observed in gate-balloon time, painballoon time and culprit artery lesion locations between the 2 study groups.
WBC, fasting glucose level, EAT and waist circumference were significantly higher in the high thrombus burden group compared to the low thrombus burden group (Fig. 1) .
The predictors of high thrombus burden were studied by multivariate logistic regression analysis. The EAT (odds ratio: 2.53, 95% CI: 1.76-3.67; P<0.001) was found as an independent predictor of high thrombus burden ( Table 2 ).
In the receiver operating characteristic(ROC) curve analysis, the thickness of 5.3 mm for EAT has 86.7% sensitivity and 82.4% specificity (AUC:0.796 95% confidence intervals: 0.715-0.876; P<0.001) (Fig. 2 ).
DISCUSSION
The present study results showed that increased EAT was an independent predictor of high thrombus burden in STEMI undergoing pPCI. To the best of our knowledge, this might be the first study investigating the relationship between EAT and coronary thrombus burden in STEMI. Epicardial adipose tissue is related with various genes associated with extracellular matrix remodeling, inflammation, infection, and thrombosis pathways 11 . Inflammatory cells play a major role both in plaque disruption through the matrix degrading metalloproteinases and in triggering thrombosis following plaque disruption through the tissue factor pathway 12 . During that process, tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1, interleukin 1β (IL-1β), interleukin 6 (IL-6), nerve growth factor, leptin, resistin, plasminogen activator inhibitor 1, and angiotensinogen especially WBC and many other pro-inflamatuar or anti-enflamatur cytokines have crucial roles within this cascade 13, 14 . Yılmaz et al. reported that lymphocyte and neutrophil counts, in particular the neutrophil/ lymphocyte ratio (NLR) could be used as independent predictors of thrombus burden in ACS (ref. 15 ). In ACS, increased neutrophils are associated with the formation of platelet-leukocyte aggregates in the vascular lumen, which causes extension of the infarct area 16 . Neutrophils can also regulate platelet function by direct adhesion and paracrine effects of secreted factors. Recent studies revealed that, coronary thrombus burden is essentially important not only for the extension of the infarct area but also for the management prior to or during the coronary interventional procedures. Celik et al. reported the contributions of CRP and inflammatory markers on microvascular injury in STEMI (ref. 17 ). High inflammatory markers may also be associated with adverse clinical outcomes in patients with ACS (ref. [18] [19] [20] . A composite marker of inflammation reflecting high trombus burden may provide additive information in the assessment of cardiovascular risk 21 . In our study, a statistically significant correlation was observed between WBC count and thrombus burden that might stem from very early PCI while acute phase reactors have not reached their peak serum levels.
Body fat distribution, especially abdominal fat tissue, is more strongly correlated to epicardial fat and biochemical proprieties of EAT suggest its possible role as a cardiovascular and metabolic risk indicator. EAT was associated with metabolic syndrome and a significant correlation between metabolic risk factors such as blood pressure, fasting glucose, insulin resistance, and hyperlipidemia has been documented 22 . Epicardial, mesenteric, and omental fat all originate from the splanchnopleuric mesoderm which is a well-known pro-inflammatory source 9, 22 . EAT releases both adiponectin and TNFα, and these two adipokines play important roles in heart diseases such as coronary artery disease 23 . Proinflammatory cytokines like IL-6, IL-1β, TNF-α stimulate the production of tissue factor in monocytes to increase platelet reactivity and to trigger the production of plasminogen activator inhibitor 1 in the liver. Moreover, IL-6 and TNF-α increase the risk of thrombosis by stimulating von Willebrand multimer secretion and another proinflammatory cytokines secreted from EAT, decreases the endothelial cell thrombomodulin expression and promotes thrombus formation 24 . Due to these facts, EAT is thought to be related to the presence and the severity of CAD, coronary plaque morphology and plaque rupture, myocardial ischemia, and major adverse cardiac events (MACE) in patient with ACS. In a recent study, increased EAT thickness were independent predictors of coronary thrombus formation in patients with NSTEMI who underwent pPCI and also coronary thrombus formation was independently associated with no-reflow phenomenon 12 . In compatible with those studies, the present study has shown that EAT was an independent predictor of coronary thrombus burden in STEMI who underwent pPCI.
Study limitations
The major limitation of this study was the small sample size. Cardiac magnetic resonance or computed tomography rather than echocardiography may give a more accurate assessment of epicardial fat amount. Adipokines and cytokines were not measured, and the exact biochemical relationship between EAT and thrombus burden was not precisely demonstrated. A prospective study is needed to determine the predictive value of EAT with high patient population. Since there was no data for predication for all of the subjects included to the study, the researchers didn't give information about the premedication of the patients. Lastly, in the present study only one blinded echocardiographer did the analysis. However, for the sake of interobserver variability there should be at least 2 independent blinded echocardiographers for the analysis.
CONClUSION
EAT was an independent predictor of coronary thrombus burden in STEMI. Whether measuring the EAT preceding the coronary intervention may have clinical value in terms of reducing the adverse cardiac event at follow up post-PCI should be investigated in a prospectively designed trials.
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